FDA’s New JAK Safety Restrictions Spell Trouble for AbbVie’s Rinvoq, but to What Extent?

From: FiercePharma

By: Angus Liu

 

A recent survey of 100 high-volume U.S. rheumatologists that Piper Sandler conducted with Spherix Global Insights showed that only 14% of patients are getting Rinvoq as prior to TNF inhibitors. And a large number of physicians are avoiding JAKs for patients with high or moderate blood clot risks.

Rinvoq is currently approved to treat moderate to severe rheumatoid arthritis after failure on methotrexate. Its label before the FDA update already included a boxed warning on blood clots, lymphoma and other malignancies and serious infections…(read more)